BeNeLuxBelgiumNetherlandsLuxembourg

Prosensa and GlaxoSmithKline expand Duchenne dystrophy alliance

24.06.2010

Leiden - Prosensa NV and British drugmaker GlaxoSmithKline have expanded their cooperation concerning RNA-modulating drugs against Duchenne muscular dystrophy (DMD). Two programmes, covering 4 drug new drug candidates for specific patient subpopulations, have been added to the existing collaboration in DMD. According to the terms of the agreement, GSK has paid two upfront fees and will add milestones dependant on research progress. Within the new programmes, Prosensa and GSK will focus on the skipping of four exons (exon 45, 52, 53, and 55), in addition to their existing programmes that target skipping of exon 51 and 44 (PRO051/GSK2402968 and PRO044). GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain limited European commercialisation rights alongside GSK for the two compounds selected by GSK. For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.

BioPeople, BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2008

Naarden – Dutch antibody specialist Pan-Genetics BV has closed a €13 million series B round led by ABN AMRO Capital, with participation from Credit Agricole Private Equity and Series A seed investor Index Ventures. In connection...

BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2008

Brussels – The Belgian government is seeking to foster corporate investment in technological innovation with tax breaks. A new law that has come into effect this year will grant patent owners tax exemptions on 80% of their patent...

BeNeLuxBelgiumNetherlandsLuxembourg

19.02.2008

Leuven/Geneva – Belgian and Swiss researchers have discovered a protein factor that could improve the response rate to anemia blockbuster erythropoietin (EPO). In mice, they found that the protein product of growth...

BeNeLuxBelgiumNetherlandsLuxembourg

19.02.2008

Amsterdam – The Dutch medicines reimbursement agency CVZ has overturned its gonadotropin clustering decision, allowing Ferring Pharmaceuticals’ human-derived gonadotropin Menopur to be clustered with higher-priced recombinant...

BeNeLuxBelgiumNetherlandsLuxembourg

19.02.2008

Amsterdam – Forbion capital has invested EUR30 million in the French biopharmaceutical company Fovea SA in Paris. Alongside Forbion, participants included the other investors, among them Sofinnova, Abingworth, GIMV, The Wellcome...

BeNeLuxBelgiumNetherlandsLuxembourg

19.02.2008

Brussels – Belgian biotech group Innogenetics welcomed a ruling by a US court, which decided that Abbott Laboratories may no longer sell products that infringe on an Innogenetics patent, but also upheld an earlier court’s...

BioFunding, BeNeLuxBelgiumNetherlandsLuxembourg

19.02.2008

Leiden – Dutch drug delivery specialist Octoplus NV has dropped its follow-on financing plans due to poor stock market conditions. The company said “it will continue to keep a close watch on the capital markets” and is evaluating...

BeNeLuxBelgiumNetherlandsLuxembourg

06.01.2008

Amsterdam – Researchers from Dutch Agendia BV have identified the tumor supressor PTEN (Phosphatase and Tensin homolog deleted on chromosome TEN) as a modulator of trastuzumab (Herceptin) resistance in breast cancer in a...

BeNeLuxBelgiumNetherlandsLuxembourg

22.11.2007

Ghent – Monsanto Co. has sold its Asian subsidiaries to Devgen. The acquisition comprises Monsanto’s hybrid rice, sunflower, sorghum and pearl millet businesses and certain other assets. Under the terms of the agreement, Devgen...

BeNeLuxBelgiumNetherlandsLuxembourg

22.11.2007

Amsterdam – The Netherlands Genomics Initiative (NGI) has announced its 2008-2012 budget plan, which has already been approved by the government. Spending will total up to a280 million and comprises the funding for several...

Displaying results 171 to 180 out of 304

< Previous 171-180 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/17/article/prosensa-and-glaxosmithkline-expand-duchenne-dystrophy-alliance.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%

FLOP

  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015

Current issue

All issues